Login to Your Account

Add pepper: Centrexion puts bite with bark in BI deal to gain pain assets

By Randy Osborne
Staff Writer

Wednesday, March 30, 2016

Centrexion Therapeutics Inc. CEO Jeffrey Kindler said his firm owns “one of the largest pipelines, if not the largest, in non-addictive chronic pain treatment,” thanks to the acquisition of three oral analgesic prospects from Boehringer Ingelheim GmbH.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription